Physician profile
Barbara E Salamon
NPI 1982669594
$1,757.04
in general payments reported to CMS, 2019-2025
15 companies · $596 in 2025
The $596 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $11.07 · 2021: $84.55 · 2022: $145 · 2023: $218 · 2024: $451 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $854.09 | 2019-2025 | Rinvoq, Skyrizi |
| Daiichi Sankyo INC. | $180.35 | 2019-2024 | Injectafer |
| Amgen INC. | $144.94 | 2019-2024 | Repatha, Otezla |
| Pfizer INC. | $109.67 | 2019-2025 | |
| Lilly USA, LLC | $104.89 | 2023-2024 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.31 | 2019-2022 | |
| Ardelyx, INC. | $60.86 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $56.33 | 2019 | |
| Ironwood Pharmaceuticals, INC | $41.67 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $34.51 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $32.65 | 2019-2024 | Rybelsus, Ozempic |
| Medtronic, INC. | $18.88 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.33 | 2021 | |
| Braintree Laboratories, INC. | $11.46 | 2019 | |
| Boston Scientific Corporation | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Salamon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.